A Phase III Study of NTQ5082 Capsules in the Treatment of Paroxysmal Nocturnal Hemoglobinuria Patients

NCT07177859 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

78

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

DRUG: NTQ5082 capsules 200 mg
DRUG: Eculizumab Injection

Sponsor

Nanjing Chia-tai Tianqing Pharmaceutical